No Data
Astellas Submits Fezolinetant New Drug Application to U.S. FDA
Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Dru
Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina
- 135,000 square-foot state-of-the-art gene therapy manufacturing facility located in Sanford, N.C., officially opened June 8 - Facility to support clinical- and commercial-scale manufacturing of Astellas' adeno-associated virus (AAV) vectors for gene
Nikkei 225 Down 0.2% on Wall Street Cues, Central Bank Outlooks
05:44 AM EDT, 06/02/2022 (MT Newswires) -- The Nikkei 225 opened lower Thursday on overnight Wall Street cues, gained in trading but still finished off 0.2% as traders weighed global inflation and tig
Astellas unit to pay $20.5M upfront to GO Therapeutics in collaboration to discover cancer therapies
Astellas Pharma's (OTCPK:ALPMY) (OTCPK:ALPMF) unit Xyphos Biosciences and GO Therapeutics are collaborating to develop novel immuno-oncology therapies. Astellas said GO is applying new advances in gly
Interstitial Cystitis Drugs Market - 36% of Growth to Originate from North America| Evolving Opportunities with Astellas Pharma Inc. & Bayer AG | 17000+ Technavio Reports
NEW YORK, June 1, 2022 /PRNewswire/ -- The "Interstitial Cystitis Drugs Market by Type (Oral therapy and Intravesical therapy) and Geography (North America, Europe, Asia, and ROW) - Forecast and Analysis 2021-2025" report has been added to Technavio's of
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and GO Therapeutics, Inc. (Co-Founder a
Amphastar announces FDA approval of generic for Astellas’ Lexiscan
Generic drugmaker Amphastar Pharmaceuticals (NASDAQ:AMPH) announced on Monday that the FDA approved its Abbreviated New Drug Application ("ANDA") for Regadenoson, a bioequivalent and therapeutically e
Astellas Pharma to Appeal US Court Decision on Patent Infringement Lawsuit
11:51 PM EDT, 05/22/2022 (MT Newswires) -- Astellas Pharma (TYO:4503) received an unfavorable ruling from the US District Court for the District of Delaware in the Lexiscan patent infringement trial,
Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress
Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new r
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to ident
Loading...